跳到正文

疾病研究与证据全景整理

查询疾病定义、表型、遗传、通路、治疗研究和流行病学资料,组织具有来源引用的研究概览。

开源精选医疗业务9 个文件1,738 Stars浏览次数 0mims-harvard/ToolUniverse Apache-2.0版本 8c6ed47
开始使用

下载前阅读 SKILL.md 中的使用条件,并确认所用工具支持对应能力。

输入资料
疾病名称与研究范围 可核查的数据库访问条件 阅读本节完整说明
交付内容
疾病研究资料 引用、检索与限制记录 阅读本节完整说明
  1. 获取完整包,保留配套文件的目录结构。
  2. 按照原文准备所需工具、依赖与输入资料。
  3. 阅读对应使用步骤与输入输出说明,在自己的环境中验证结果。

使用提示摘自原文,配套文件保留来源版本;实际运行条件以各包说明为准。

正文

获取原文件

SKILL.md

中文导读

查询疾病定义、表型、遗传、通路、治疗研究和流行病学资料,组织具有来源引用的研究概览。

输入材料

  • 疾病名称与研究范围
  • 可核查的数据库访问条件

交付结果

  • 疾病研究资料
  • 引用、检索与限制记录

阅读与使用

本页保存指定版本的原始 Skill 和配套文件,可查看中文导读、原文与参考资料。获取完整包后,按原文准备所需工具与材料。执行需要 ToolUniverse SDK 或 MCP 服务,部分数据库需要独立访问权限。医疗资料供研究、资料整理和专业人员复核,试验资格、用药与诊疗结论需要核实当前来源。

来源仓库为 mims-harvard/ToolUniverse,采用 Apache-2.0 许可。Stars 表示仓库关注度,核验日期为 2026-10-15。分类表示适用的工作环节,实际执行条件以原文为准。

原始 Skill

Generate a comprehensive disease research report with full source citations. The report is created as a markdown file and progressively updated during research.

IMPORTANT: Always use English disease names and search terms in tool calls. Respond in the user's language.


LOOK UP, DON'T GUESS

When asked about a disease, query Orphanet/OMIM/DisGeNET FIRST. Don't rely on memory for prevalence, genetics, or treatment — these change over time. When you're not sure about a fact, your first instinct should be to SEARCH for it using tools, not to reason harder from memory.


When to Use

  • User asks about any disease, syndrome, or medical condition
  • Needs comprehensive disease intelligence or a detailed research report
  • Asks "what do we know about [disease]?"

Core Workflow: Report-First Approach

DO NOT show the search process to the user. Instead:

  1. Create report file first - Initialize {disease_name}_research_report.md
  2. Research each dimension - Use all relevant tools
  3. Update report progressively - Write findings after each dimension
  4. Include citations - Every fact must reference its source tool

Disease Mechanism Reasoning

When synthesizing disease etiology, trace the full pathogenic cascade:

  1. Genetic basis - Which variants (rare or common) confer risk, and in which genes?
  2. Molecular mechanism - How do those variants alter protein function, expression, or regulation?
  3. Cellular effect - What downstream cellular processes are disrupted (signaling, metabolism, stress response)?
  4. Tissue/organ manifestation - How does cellular dysfunction present as organ-level pathology?

This chain structures the Genetic & Molecular Basis (Section 3) and Biological Pathways (Section 5) sections.


10 Research Dimensions

Dim Section Key Tools
1 Identity & Classification OSL_get_efo_id_by_disease_name, ols_search_efo_terms, ols_get_efo_term, umls_search_concepts, icd_search_codes, snomed_search_concepts
2 Clinical Presentation OpenTargets phenotypes, HPO lookup, MedlinePlus
3 Genetic & Molecular Basis OpenTargets targets, ClinVar variants, GWAS associations, gnomAD
4 Treatment Landscape OpenTargets drugs, clinical trials, GtoPdb
5 Biological Pathways Reactome pathways, humanbase_ppi_analysis, GTEx expression, HPA
6 Epidemiology & Literature PubMed, OpenAlex, Europe PMC, Semantic Scholar
7 Similar Diseases OpenTargets similar entities
8 Cancer-Specific (if applicable) CIViC genes/variants/therapies
9 Pharmacology GtoPdb targets/interactions/ligands
10 Drug Safety OpenTargets warnings, clinical trial AEs, FAERS

See: tool_usage_details.md for complete tool calls per section.

Normalizing free text to ontology IDs (Dimension 1)

When the input is messy free text (a sample attribute, a synonym, a tissue/organism label) rather than a clean disease name, use ZOOMA_annotate_text to map it to standardized ontology terms (EFO/MONDO/UBERON/etc.) before lookup. It returns each match as an ontology IRI with a confidence rating (HIGH/GOOD/MEDIUM/LOW), so you can keep only high-confidence hits and feed the resolved ID into OLS / OpenTargets.

tu.run_tool("ZOOMA_annotate_text", {
    "property_value": "asthma",        # free text to resolve
    "property_type": "disease",         # optional context hint
    "min_confidence": "HIGH",           # drop fuzzy matches
    "max_results": 3,
})
# -> [{"semantic_tags": ["http://purl.obolibrary.org/obo/MONDO_0004979"],
#      "curies": ["MONDO:0004979"], "confidence": "HIGH", "source": "zooma", ...}]

# Restrict to one ontology source (e.g. EFO) when you need a specific namespace:
tu.run_tool("ZOOMA_annotate_text", {"property_value": "diabetes", "ontologies": "efo"})

# Inspect which curated datasources back ZOOMA annotations (for provenance):
tu.run_tool("ZOOMA_list_datasources", {})
# -> [{"name": "eva-clinvar", "type": "DATABASE", "uri": "https://www.ebi.ac.uk/eva"}, ...]

Each match also carries a ready-to-use curies field (e.g. MONDO:0004979) so you can feed the resolved ID straight into OLS / OpenTargets without parsing the IRI. ZOOMA is the live replacement for the retired OxO cross-reference service; pair it with ols_get_efo_term to expand the resolved IRI into labels, synonyms, and hierarchy.


Report Template

Create this file structure at the start:

# Disease Research Report: {Disease Name}

**Report Generated**: {date}
**Disease Identifiers**: (to be filled)

---

## Executive Summary
(Brief 3-5 sentence overview - fill after all research complete)

---

## 1. Disease Identity & Classification
### Ontology Identifiers
| System | ID | Source |

### Synonyms & Alternative Names
### Disease Hierarchy

---

## 2. Clinical Presentation
### Phenotypes (HPO)
| HPO ID | Phenotype | Description | Source |

### Symptoms & Signs
### Diagnostic Criteria

---

## 3. Genetic & Molecular Basis
### Associated Genes
| Gene | Score | Ensembl ID | Evidence | Source |

### GWAS Associations
| SNP | P-value | Odds Ratio | Study | Source |

### Pathogenic Variants (ClinVar)

---

## 4. Treatment Landscape
### Approved Drugs
| Drug | ChEMBL ID | Mechanism | Phase | Target | Source |

### Clinical Trials
| NCT ID | Title | Phase | Status | Source |

---

## 5. Biological Pathways & Mechanisms

## 6. Epidemiology & Risk Factors

## 7. Literature & Research Activity

## 8. Similar Diseases & Comorbidities

## 9. Cancer-Specific Information (if applicable)

## 10. Drug Safety & Adverse Events

---

## References
### Tools Used
| # | Tool | Parameters | Section | Items Retrieved |

Citation Format

Every piece of data MUST include its source:

In tables: Add a Source column with tool name In lists: - Finding [Source: tool_name] In prose: (Source: tool_name, query: "...") References section: Complete tool usage log with parameters


Progressive Update Pattern

# After each dimension's research:
# 1. Read current report
# 2. Replace placeholder with formatted content
# 3. Write back immediately
# 4. Continue to next dimension

Evidence Grading & Interpretation

Every finding in the report should be graded:

Grade Criteria Example
T1 (Strong) Replicated genetic evidence (GWAS, rare variants), FDA-approved therapy BRCA1 → breast cancer; trastuzumab for HER2+
T2 (Moderate) Single genetic study, phase II+ trial data, strong biological evidence FOXO3 → longevity (centenarian studies)
T3 (Association) Observational data, gene expression changes, pathway membership IL-6 elevated in Alzheimer's CSF
T4 (Computational) Network proximity, text mining, predicted associations DisGeNET text-mined gene-disease link

Synthesis Questions (answer in Executive Summary)

After collecting data from all 10 dimensions, the report MUST answer:

  1. What causes this disease? Summarize the genetic architecture (monogenic vs polygenic, key loci, penetrance)
  2. What are the therapeutic options? Ranked by evidence level and approval status
  3. What biomarkers exist? For diagnosis, prognosis, and treatment selection
  4. What's the unmet need? What aspects lack effective treatment or understanding?
  5. What are the active research frontiers? Based on clinical trials and recent publications

Interpreting Cross-Database Concordance

When multiple databases provide different data for the same disease:

  • OpenTargets + DisGeNET + OMIM agree on a gene: T1 evidence — high confidence
  • Only OpenTargets reports an association: Check the datasource scores — genetic_association > literature > animal_model
  • DisGeNET score > 0.5 but not in OpenTargets: May be text-mined; verify with PubMed
  • Gene in GWAS but not OMIM: Likely a complex disease susceptibility locus, not Mendelian

Handling Conflicting Data

Conflict Resolution
Different prevalence estimates across sources Report range; note the most recent/largest study
Drug approved in one country but not another Note regulatory status per region
Gene-disease association in one DB but absent in another Grade by evidence type; text-mining alone is T4
Clinical trial results contradict label indications The trial result is newer evidence; note both

Final Report Quality Checklist

  • All 10 sections have content (or marked "No data available")
  • Every data point has a source citation
  • Executive summary reflects key findings
  • References section lists all tools used
  • Tables properly formatted
  • No placeholder text remains

Expected Output Scale

For a well-studied disease (e.g., Alzheimer's), the final report should include:

  • 5+ ontology IDs, 10+ synonyms, disease hierarchy
  • 20+ phenotypes with HPO IDs
  • 50+ genes, 30+ GWAS associations, 100+ ClinVar variants
  • 20+ drugs, 50+ clinical trials
  • 10+ pathways, PPI network, expression data
  • 100+ publications
  • 15+ similar diseases
  • Drug warnings and adverse events

Total: 500+ individual data points, each with source citation.


Cross-Skill References

For rare disease differential diagnosis, run: python3 skills/tooluniverse-rare-disease-diagnosis/scripts/clinical_patterns.py --type differential --symptoms 'symptom1,symptom2'


Reference Files

CONTACT HAONAN

联系haonan

医疗 AI · 产品与独立开发

刘浩南

关注医疗 AI 从 demo 到真实落地,聚焦产品化、商业化与院内工作流效率提升。

12年医疗产研经验,大湾区头部医疗AI公司前产品总监,独立开发者

医疗 AI 产品化医疗 AI 商业化院内工作流效率
刘浩南的微信联系二维码
微信扫一扫,联系 haonan